| 1 |
Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev 2013; 8: CD008980.
doi: 10.1002/14651858.CD008213.pub3
pmid: 32816311
|
| 2 |
Enriquez A, Lip GY, Baranchuk A. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. Europace 2015 Mar 26. pii: euv030. [Epub ahead of print]
pmid: 33279992
|
| 3 |
Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticogulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013; 34:2094-2106.
doi: 10.1093/eurheartj/eht134
pmid: 23625209
|
| 4 |
Lai A, Davidson N, Galloway SW, Thachil J. Perioperative management of patients on new oral anticoagulants. Br J Surg 2014; 101:742-749.
|
| 5 |
Dinkelaar J, Patiwael S, Harenberg J, Leyte A, Brinkman HJ. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate. Clin Chem Lab Med 2014; 52:1615-1623.
doi: 10.1515/cclm-2014-0307
pmid: 24902009
|
| 6 |
Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost 2015; 113:931-942.
|
| 7 |
Crowther M. CS.03: Management of Cardiovascular Disease. Presented at: American Heart Association Scientific Sessions; Nov. 15-19, 2014; Chicago.
|
| 8 |
Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014; 371:2141-2142.
doi: 10.1056/NEJMc1411800
pmid: 25371966
|
)
